¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"intermittent rhythmic delta activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibacterial activity
    Ç×±ÕÀÛ¿ë
  • activity
    1. Ȱ¼ºµµ 2. Ȱµ¿, Ȱ¼º 3. -´É
  • biologic activity
    »ý¹°ÇÐÀûȰ¼º
  • caries activity
    ¿ì½ÄȰµ¿
  • electrical activity
    Àü±âȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É, ÇǺ기¿ëÇØ´É
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÇàÀ§
  • involuntary activity
    ºÒ¼öÀÇȰµ¿
  • insertion activity
    »ðÀÔȰµ¿ÀüÀ§
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • integrated neural activity
    ÅëÇսŰæÈ°¼º
  • molar activity
    ¸ôȰ¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • activity
    Ȱ¼ºµµ, Ȱµ¿
  • activity therapist
    Ȱµ¿¿ä¹ý»ç, Ȱµ¿Ä¡·á»ç
  • activity therapy
    Ȱµ¿¿ä¹ý
  • antibacterial activity
    Ç×±ÕÀÛ¿ë
  • caries activity
    ¿ì½ÄȰµ¿¼º
  • electrical activity
    Àü±âȰµ¿
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É
  • helper cell activity
    µµ¿ò¼¼Æ÷´É, Á¶·Â¼¼Æ÷´É
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÇàÀ§
  • insertion activity
    »ðÀÔȰµ¿ÀüÀ§
  • integrated neural activity
    ÅëÇսŰæÈ°¼º
  • involuntary activity
    ºÒ¼öÀÇȰµ¿
  • mental activity
    Á¤½ÅȰµ¿
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • delta-aminolevulinic acid
    µ¨Å¸-¾Æ¹Ì³ë·¹ºÒ¸°»ê.
  • delta-aminolevulinic acid dehydrase
    µ¨Å¸-¾Æ¹Ì³ë·¹ºÒ¸°»êÅ»¼ö¼ÒÈ¿¼Ò<--µ¥È÷µå¶óÁ¦>
  • delta-aminolevulinic acid dehydrogenase
    µ¨Å¸-¾Æ¹Ì³ë·¹ºÒ¸°»êÅ»¼ö¼ÒÈ¿¼Ò<--µðÇÏÀ̵å·Î°Ô³ªÁ¦>
  • delta-aminolevulinic acid synthetase
    µ¨Å¸-¾Æ¹Ì³ë·¹ºÒ¸°»êÇÕ¼ºÈ¿¼Ò
  • delta-beta thalassmia
    µ¨Å¸-º£Å¸ ÁöÁßÇØºóÇ÷
  • gamma-delta-beta thalassemia
    °¨¸¶-µ¨Å¸-º£Å¸- ÁöÁßÇØ¼ººóÇ÷
  • hepatitis,delta
    µ¨Å¸
  • acute intermittent porphyria
    ±Þ¼º °£Ç漺(Ðáàõ ÊàúÎàõ) Æ÷¸£ÇǸ°Áõ(~ ñø)
  • acute intermittent porphyria
    ±Þ¼º °£Ç漺 (?˧̴ËÛ) Æ÷¸£ÇǸ®¾Æ(Áõ).
  • acute intermittent porphyria
    ±Þ¼º °£Ç漺 (¡­ÊàúÎàõ) Æ÷¸£ÇǸ®¾Æ(Áõ).
  • asymptomatic intermittent proteinuria
    ¹«Áõ»ó°£Ç漺 ´Ü¹é´¢(¡­Ó±ÛÜèñ).
  • automatic intermittent positive pressure
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
  • automatic intermittent positive pressure respir ator
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
  • automatic intermittent positive pressure respirator
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
  • clean intermittent catheterization
    û°á °£ÇæÀû µµ´¢
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
ALADH delta-aminolevulinate dehydratase
ALAS delta-aminolevulinate synthase
ALASH delta-aminolevulinate synthase, housekeeping type
DALA delta-aminolevulinic acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CIC Clean intermittent catheterisation
CISC Clean intermittent self catheterisation
IC Intermittent Claudication
IMV Intermittent Mandatory Ventilation
IPD Intermittent Peritoneal Dialysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electrical activity
    Àü±âÀû Ȱ¼º
  • fidgeting activity
    ¾ÈÀýºÎÀýÇϴ Ȱµ¿
  • helper cell activity
    ÇïÆÛ ¼¼Æ÷ Ȱ¼º
  • impaired occupational activity
    »çȸÀû ¹× Á÷¾÷Àû Ȱµ¿ Àå¾Ö, Á÷¾÷Àû Ȱµ¿ Àå¾Ö
  • impaired social activity
    »çȸÀû Ȱµ¿ Àå¾Ö
  • intrinsic sympathomimetic activity
    ³»Àμº ±³°¨½Å°æ À¯»ç ÀÛ¿ë
  • lip activity
    ÀÔ¼ú ¿îµ¿, ÀÔ¼ú Ȱµ¿·Â
  • maintained activity
    Ȱ¼º À¯Áö
  • mental activity
    Á¤½Å Ȱµ¿
  • molar activity
    ¸ô Ȱ¼º
  • muscle activity
    ±Ù Ȱ¼º
  • muscular activity
    ±ÙÀ° Ȱµ¿, ±Ù Ȱ¼ºµµ
  • neuromuscular reflex activity
    ±Ù½Å°æ ¹Ý»ç Ȱµ¿
  • nociceptor activity
    Ä§ÇØ ¼ö¿ëü Ȱ¼º, À¯ÇØ ¼ö¿ë±â Ȱ¼º
  • partial agonistic activity
    ºÎºÐ È¿´É, ºÎºÐ È¿´ÉÀû Ȱ¼º, ºÎºÐ È¿ÇöÀû Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
blocking activity The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus.
(05 Mar 2000)
blood bactericidal activity Native bactericidal property of blood due to normally occurring antibacterial substances such as beta lysin, leukin, etc.
(12 Dec 1998)
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
water activity <chemistry> An expression of the relative availability of water in a substance. Pure water has an water activity of 1.000. The water activity of a solution is one-hundredth its relative humidity.
(09 Oct 1997)
motor activity The physical activity of an organism as a behavioural phenomenon.
(12 Dec 1998)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plasma renin activity The estimation of renin in plasma by measuring the rate of formation of angiotensin I or II.
(05 Mar 2000)
solar activity Any type of variation in the appearance of energy output of the sun.
(12 Dec 1998)
specific activity 1. <chemistry> The number of activity units (whatever is appropriate) per unit of mass, volume or molarity.
2. <radiobiology> Total activity of a given nuclide per gram of a compound, element or radioactive nuclide. Perhaps most often usage, in the context of radiochemicals, the number of microcuries per micromole.
(16 Dec 1997)
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
intrinsic sympathomimetic activity The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á